Tags

Type your tag names separated by a space and hit enter

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
J Virol. 2021 11 09; 95(23):e0131321.JV

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.

Authors+Show Affiliations

Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.Moderna, Inc., Cambridge, Massachusetts, USA.

Pub Type(s)

Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

34549975

Citation

Choi, Angela, et al. "Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants." Journal of Virology, vol. 95, no. 23, 2021, pp. e0131321.
Choi A, Koch M, Wu K, et al. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. J Virol. 2021;95(23):e0131321.
Choi, A., Koch, M., Wu, K., Dixon, G., Oestreicher, J., Legault, H., Stewart-Jones, G. B. E., Colpitts, T., Pajon, R., Bennett, H., Carfi, A., & Edwards, D. K. (2021). Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. Journal of Virology, 95(23), e0131321. https://doi.org/10.1128/JVI.01313-21
Choi A, et al. Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants. J Virol. 2021 11 9;95(23):e0131321. PubMed PMID: 34549975.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. AU - Choi,Angela, AU - Koch,Matthew, AU - Wu,Kai, AU - Dixon,Groves, AU - Oestreicher,Judy, AU - Legault,Holly, AU - Stewart-Jones,Guillaume B E, AU - Colpitts,Tonya, AU - Pajon,Rolando, AU - Bennett,Hamilton, AU - Carfi,Andrea, AU - Edwards,Darin K, Y1 - 2021/09/22/ PY - 2021/9/23/pubmed PY - 2021/11/19/medline PY - 2021/9/22/entrez KW - COVID-19 KW - SARS-CoV-2 variants of concern KW - mRNA-1273 KW - neutralization SP - e0131321 EP - e0131321 JF - Journal of virology JO - J Virol VL - 95 IS - 23 N2 - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19. SN - 1098-5514 UR - https://www.unboundmedicine.com/medline/citation/34549975/Serum_Neutralizing_Activity_of_mRNA_1273_against_SARS_CoV_2_Variants_ L2 - https://journals.asm.org/doi/10.1128/JVI.01313-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -